Targeted Nanomedicine for Breast Cancer Therapy

Recently, scientists from the Agharkar Research Institute (ARI), Pune, developed a next-generation nanomedicine platform that selectively targets and silences genes responsible for breast cancer growth, offering a promising approach for precision cancer treatment.

Key Points

Technology Used: Researchers designed biodegradable mesoporous silica nanoparticles capable of efficiently delivering therapeutic molecules directly to tumour cells.
Targeted Delivery: The nanoparticles were functionalised with a protamine biopolymer and an MUC1-specific aptamer, enabling selective recognition and binding to MUC1 receptors overexpressed on breast cancer cells.
Dual Gene Silencing: The platform simultaneously delivers small interfering RNA (siRNA) molecules targeting two anti-apoptotic genes – MCL-1 and Survivin – which help cancer cells survive and resist treatment.
Experimental Results: Studies on MCF-7 breast cancer models showed significant suppression of both target genes, increased cancer cell death, and substantial inhibition of tumour growth.
Key Advantage: The platform combines targeted delivery, stimuli-responsive drug release, and combinatorial gene silencing within a single biodegradable nanocarrier system.